MDxHealth SA R&D Spending Growth & History (MDXH)
MDxHealth SA's r&d spending was $10.3M for fiscal 2025.
View full MDxHealth SA company overviewMDxHealth SA annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.3M | −$202,000 | −1.91% |
| 2024 | 2024-12-31 | $10.6M | $4.2M | +65.50% |
| 2023 | 2023-12-31 | $6.4M | $879,000 | +15.99% |
| 2022 | 2022-12-31 | $5.5M | −$92,000 | −1.65% |
| 2021 | 2021-12-31 | $5.6M | $1.0M | +23.02% |
| 2020 | 2020-12-31 | $4.5M | −$4.5M | −49.51% |
| 2019 | 2019-12-31 | $9.0M | — | — |
MDxHealth SA quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.0M | $136,000 | +7.32% |
| Q1 2026 | 2026-03-31 | $2.1M | −$365,000 | −14.61% |
| Q4 2025 | 2025-12-31 | $3.3M | — | — |
| Q3 2025 | 2025-09-30 | $2.0M | — | — |
| Q2 2025 | 2025-06-30 | $1.9M | — | — |
| Q1 2025 | 2025-03-31 | $2.5M | — | — |
MDxHealth SA r&d spending trends
Over the last five fiscal years, MDxHealth SA's r&d spending increased from $4.5M to $10.3M, a change of $5.8M. The latest reported quarter, Q2 2026, shows $2.0M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MDxHealth SA source filings ↗